Korify Capital

Korify Capital, based in Basel, Switzerland, focuses on early and growth-stage investments in the biotech sector, particularly targeting longevity and mental health. Launched by Robin and Peter Lauber’s family office, Infinitas Capital, Korify Capital aims to drive forward breakthrough technologies that can extend healthy lifespan and address mental health issues. Notable investments include Alto Neuroscience, which uses AI-derived brain biomarkers to develop psychiatric treatments, and Cambrian Biopharma, which is pioneering therapeutics to lengthen healthspan by targeting the biological drivers of aging. Another significant investment is Gameto, which focuses on improving assisted fertility and tackling ovarian aging through cellular reprogramming. Korify Capital also invests in companies like Refoxy, which develops medicines to treat age-related diseases by modulating stress response pathways, and Rejuveron, a biotech firm aiming to transform aging-related scientific discoveries into practical treatments. These investments demonstrate Korify’s commitment to supporting innovative approaches in the biotech field, aiming to enhance longevity and overall health. The firm’s strategy involves leveraging its extensive venture capital network and deep expertise in biotech to support these transformative companies, helping them achieve significant milestones and growth.